The Importance of Including Long COVID Outcomes When Developing Novel Treatments for Acute COVID-19

J Infect Dis. 2024 Oct 16;230(4):789-796. doi: 10.1093/infdis/jiae270.

Abstract

Amid efforts to develop effective treatments for acute COVID-19, there is growing recognition of the need to address long COVID as a key outcome measure. We argue there are 7 compelling reasons to include long COVID measurements in clincal trials investigating acute COVID-19 treatments: (1) Long COVID is not rare. (2) Long COVID is debilitating to individuals and has a high societal cost. (3) Those at high risk of severe COVID-19 are also at higher risk of developing long COVID if they are infected with COVID-19. (4) Treatments for acute COVID-19 may reduce the risk of long COVID. (5) Measures exist to track long COVID. (6) Long COVID considerations are potentially important for acute COVID-19 treatment decision making. (7) Deaths and hospitalizations due to COVID-19 are increasingly rare. While not every trial needs to include assessments of long COVID, it is worth the research burden to include assessments where possible, as this could facilitate the uptake of acute COVID-19 treatments that lessen the societal burden of long COVID.

Keywords: COVID-19; clinical trials; long COVID; novel treatments; trial outcomes.

MeSH terms

  • COVID-19 Drug Treatment
  • COVID-19* / therapy
  • Clinical Trials as Topic
  • Hospitalization
  • Humans
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2*
  • Treatment Outcome